Please assess the completion status of the following clinical trial:

Trial Title: Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hemodialysis patients undergoing 4-hour-long HD thrice a week for at least 2 years~* With an average serum potassium level (immediately before dialysis on the first day of the week) of \<6.5 mEq/l over the previous 2 months~* With a 24-hour urine output of \<500 ml~Exclusion Criteria:~* A history of noncompliance~* Unstable vascular access~* Hypotension~* Hepatic failure~* Active cancer~* Any life-threatening disease other than ESRD

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- spironolactone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).